Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

planned in metastatic breast cancer.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for leading biopharmaceutical company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.  In addition to the releasable polymer technology, Nektar is the first company to create a permanent small molecule-polymer conjugate with enhanced oral bioavailability and restricted entry into the CNS.  Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas.  Nektar entered into an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 program for the treatment of pain without constipation side effects.  NKTR-102 is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers.  NKTR-105 is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect Nektar's current views regarding the potential of its technology platform, the potential of
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli Lilly ... of its long-standing technology transfer program to increase the ... in 2003, the effort included Lilly donating manufacturing technology ... China , India ... South Africa – all MDR-TB ,hot spots., ...
(Date:10/27/2014)... 27, 2014 Research and Markets has ... 2014-2018" report to their offering. H1N1 ... a variant of the swine H1N1 virus, known as H1N1v ... nose, throat, and lungs. H1N1 virus is an RNA virus ... animal species such as humans, swine, birds, seals, and horses. ...
(Date:10/27/2014)... EAST TAUNTON, Mass. , Oct. 27, 2014 /PRNewswire/ ... the $15 billion global hip and knee replacement device market, ... and knee replacement technology at the American Association of ... the Sheraton Dallas Hotel in Dallas, Texas ... is a Bronze corporate partner of the organization. ...
Breaking Medicine Technology:Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 2OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 3
... Bulletin Board: GOVX ) announced today the publication ... its HIV/AIDS vaccine products. The article, titled "Phase 1 Safety ... Vaccines Expressing HIV-1 Virus-like Particles," will appear in the March ... Diseases . A PDF of the article is available at ...
... Inc., a leader in room temperature biostability technology, ... (IQT). IQT is the independent, strategic investment firm ... mission of the U.S. Intelligence Community. ... pioneered recent innovations in ambient storage of biological ...
Cached Medicine Technology:GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 2GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 3GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 4Biomatrica Secures Strategic Investment from IQT 2Biomatrica Secures Strategic Investment from IQT 3
(Date:10/30/2014)... at least 2 years old to be covered by ... guidance exists other than the general recommendation by national ... least the first six months. , So what ... that motivated researchers at the University at Buffalo School ... patterns of American infants at 6 months and 12 ...
(Date:10/30/2014)... Timothy, InstaKNOT’s 4-year-old CEO, ... showing that you are never too young to give ... Tracey and Carl at the 2013 Santa Arriving By ... Beach Chamber of Commerce. Tracey gave Timothy a special ... wear his real fireman’s hat, and extending an offer ...
(Date:10/30/2014)... Five months after their expansion, the ... new branding and a website to accompany their recent ... Mepham’s promotion to name partner earlier this year, Hodgkinson ... Mepham’s name and better reflect their combined litigation expertise. ... decision to implement new branding reflects Hodgkinson Street Mepham’s ...
(Date:10/30/2014)... Reinberg HealthDay Reporter , WEDNESDAY, ... men with prostate cancer who also have certain heart problems ... a new study suggests. , , The therapy in question is ... to reduce levels of male hormones to prevent the growth ... current research, this hormone therapy was linked to triple the ...
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, has ... GYN in Melrose Park, IL and OB GYN ... about each of the care services and practice areas that ... and Spanish. The navigation of the website is easy ... Dr. Furlin’s patients with important information regarding his care methods ...
Breaking Medicine News(10 mins):Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Hodgkinson Street Mepham Rebrands 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2
... Aug. 25 HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) a ... for the second quarter ended June 30, 2009. The company ... in prescription sales and pharmacy transfers. Gross margins increased 7.8% ... $396,271. , , "Consumers are increasingly switching ...
... FT. WASHINGTON, Pa., Aug. 25 The makers of ZYRTEC(R) ... announced the availability of two new allergy solutions to help ... Children,s ZYRTEC(R) PERFECT MEASURE(R) and ZYRTEC(R) Itchy Eye Drops are ... products. The company also announced the launch of AllergyCast, ...
... , CHICAGO, Aug. 25 Health care costs are ... according to Aon Consulting, the global human capital consulting organization of ... (NYSE: AOC ). , , ... more than 60 leading health care insurers, representing more than 100 million ...
... food has been detected in unusually high levels in ... condition pre-eclampsia. These results are important because they ... pre-eclampsia and may help scientists to understand the cause ... at the University of Leeds took blood samples from ...
... polyps, sessile serrated polyps (also called sessile serrated adenomas), ... polyps share molecular features with a subgroup of colon ... be precursors of cancer through a hyperplastic polyp to ... arise in the proximal colon. Sessile serrated polyps may ...
... that connective tissue growth factor (CCN2) plays a ... systems. Fibrosis is a scarring condition that is ... cell function and can cause organ dysfunction and ... liver is the activation of hepatic stellate cells ...
Cached Medicine News:Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 2Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 3Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 2Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 3Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 4Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 2Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 3Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 4Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 5Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 6Health News:New link between pre-eclampsia and diet 2Health News:Reinterpretation of proximal colon polyps called hyperplastic in 2001 2
Span Diagnostics Limited...
Malaria (P. fal.) Ag Rapid Test...
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria)....
... The NOW® Malaria Test is a field or ... Malaria infection. It is intended for the detection ... and an antigen that is common to all ... (P.f.), Plasmodium vivax (P.v.), Plasmodium ...
Medicine Products: